{
    "nct_id": "NCT05100862",
    "official_title": "A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma",
    "inclusion_criteria": "* Histologically confirmed grade 1-3a FL or MZL\n* Previously treated with â‰¥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy\n* Need for systemic therapy for FL or MZL\n* Measurable disease by computed tomography or magnetic resonance imaging\n* Adequate bone marrow, liver and renal function\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Transformation to aggressive lymphoma\n* Requiring ongoing need for corticosteroid treatment\n* Clinically significant cardiovascular disease\n* Prior malignancy within the past 2 years\n* Active fungal, bacterial, and/or viral infection that requires systemic therapy\n* Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (< 24 months)\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}